狄诺塞麦价格多少？

Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody, RANKL inhibitor, indicated for the treatment of osteoporosis, therapy-induced bone loss, metastasis to bone, and giant cell tumor of bone. Works by preventing the development of osteoclasts, cells that break down bone (bone resorption). Denosumab, developed by biotech company Amgen, reduces the risk of fractures in cancer patients. Denosumab is contraindicated in people with low blood calcium levels. The most common side effects are joint and muscle pain in the arms or legs.

On May 28, 2010, the European Commission approved this product for the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. On June 2, 2010, the brand name Prolia was approved by the United States (FDA) for use in postmenopausal women with the risk of osteoporosis. On October 26, 2018, Amgen Pharmaceuticals submitted a marketing application in China, with the application name: denosumab. On May 23, 2019, China’s National Medical Products Administration announced conditional approval of the import registration application for Denosumab Injection (English name: Denosumab Injection). The drug will be used to treat adults and skeletally mature adolescent patients with unresectable giant cell tumors of bone or whose surgical resection may result in severe functional impairment.

The price of drugs is something that everyone is concerned about. So, how much does denosumab (denosumab) cost?

At present, we have no way of knowing the price in China. The specifications of denosumab in the United States are: 60mg/1ml tube/box, price: $1,169.98/unit: US dollars; specification: 120mg/1.7ml bottle/box, price: $2,391.11/unit: US dollars. The price of denosumab is the lowest in Türkiye, with a specification of 125mg/1ml tube/box and a price of about $3,000.